LION-101 Gene Therapy for Rare MD Type Now on FDA Fast Track

LION-101 Gene Therapy for Rare MD Type Now on FDA Fast Track

298468

LION-101 Gene Therapy for Rare MD Type Now on FDA Fast Track

The U.S. Food and Drug Administration (FDA) has granted fast track designation to LION-101, an investigational gene therapy that Asklepios BioPharmaceutical (AskBio) is developing as a treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This designation is given to therapies designed to fill an unmet need in medical care for serious conditions, with the overall aim of getting treatments to patients more quickly. The designation confers certain benefits, including more frequent meetings with the FDA to discuss…

You must be logged in to read/download the full post.